{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:47:57Z","timestamp":1791478077487,"version":"4.3.4"},"reference-count":161,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,2,22]],"date-time":"2017-02-22T00:00:00Z","timestamp":1487721600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Nutrition Food Res"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:p>Methylxanthines (MTXs) are consumed by almost everybody in almost every area of the world. Caffeine, theophylline and theobromine are the most well\u2010known members of this family of compounds; they are present, <jats:italic>inter alia<\/jats:italic>, in coffee, tea, cacao, yerba mate and cola drinks. MTXs are readily absorbed in the gastrointestinal tract and are able to penetrate into the central nervous system, where they exert significant psychostimulant actions, which are more evident in acute intake. Coffee has been paradigmatic, as its use was forbidden in many diseases, however, this negative view has radically changed; evidence shows that MTXs display health benefits in diseases involving cell death in the nervous system. This paper reviews data that appraise the preventive and even therapeutic potential of MTXs in a variety of neurodegenerative diseases. Future perspectives include the use of MTXs to advance the understanding the pathophysiology of, <jats:italic>inter alia<\/jats:italic>, Alzheimer's disease (AD) and Parkinson's disease (PD), and the use of the methylxanthine chemical moiety as a basis for the development of new and more efficacious drugs.<\/jats:p>","DOI":"10.1002\/mnfr.201600670","type":"journal-article","created":{"date-parts":[[2017,1,11]],"date-time":"2017-01-11T08:23:19Z","timestamp":1484122999000},"source":"Crossref","is-referenced-by-count":79,"title":["Health benefits of methylxanthines in neurodegenerative diseases"],"prefix":"10.1002","volume":"61","author":[{"given":"Ainhoa","family":"O\u00f1atibia\u2010Astibia","sequence":"first","affiliation":[{"name":"Official College of Pharmacists of Gipuzkoa  San Sebastian Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Franco","sequence":"additional","affiliation":[{"name":"Molecular Neurobiology laboratory Department of Biochemistry and Molecular Biomedicine Faculty of Biology University of Barcelona  Barcelona Spain"},{"name":"CIBERNED Centro de Investigaci\u00f3n en Red, Enfermedades Neurodegenerativas Instituto de Salud Carlos III  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Mart\u00ednez\u2010Pinilla","sequence":"additional","affiliation":[{"name":"Instituto de Neurociencias del Principado de Asturias (INEUROPA) Departamento de Morfolog\u00eda y Biolog\u00eda Celular, Facultad de Medicina Universidad de Oviedo  Asturias Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,2,22]]},"reference":[{"key":"e_1_2_7_2_1","unstructured":"World Health Organization.Global Health and Aging.http:\/\/www.who.int\/ageing\/publications\/global_health.pdf29th September2016."},{"key":"e_1_2_7_3_1","unstructured":"World Bank Group.The World Bank IBRD\u2010IDA.http:\/\/data.worldbank.org\/indicator1st March2016."},{"key":"e_1_2_7_4_1","first-page":"2145","article-title":"Global, regional, and national disability\u2010adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990\u20132013: quantifying the epidemiological transition","volume":"28","author":"GBD 2013 DALYs and HALE Collaborators","year":"2015","journal-title":"Lancet"},{"key":"e_1_2_7_5_1","unstructured":"Bendorf A. World Population Trends Towards 2050 and Beyond.http:\/\/www2.warwick.ac.uk\/fac\/soc\/pais\/research\/researchcentres\/csgr\/green\/foresight\/demography\/2010_fdi_world_population_trends_towards_2050_and_beyond.pdf20th February2016."},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/nu5104159"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2016.01.022"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-13443-2_4"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2014.10.051"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-13443-2_10"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050019"},{"key":"e_1_2_7_12_1","first-page":"30","article-title":"The relevance of theobromine for the beneficial effects of cocoa consumption","volume":"6","author":"Mart\u00ednez\u2010Pinilla E.","year":"2015","journal-title":"Front. Pharmacol."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-201x.2000.00742.x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001112"},{"key":"e_1_2_7_15_1","first-page":"1046","article-title":"Regular consumption of cocoa powder with milk increases HDL cholesterol and reduces oxidized LDL levels in subjects at high\u2010risk of cardiovascular disease","volume":"22","author":"Khan N.","year":"2012","journal-title":"Nutr. Metab."},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.3945\/ajcn.112.047373"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-13443-2_3"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2010.02.020"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.108.048207"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309363"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-013-0063-z"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.12.025"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1542\/neo.14-11-e540"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13001"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.079319"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12640-012-9372-1"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2002.00928.x"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.2002.01210.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/glia.22290"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2014.01.083"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2009.09.001"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11064-009-9945-4"},{"key":"e_1_2_7_33_1","first-page":"319","article-title":"Paradoxical effects of adenosine receptor ligands on hydroxyl radical generation by L\u2010DOPA in the rat striatum","volume":"60","author":"Go\u0142embiowska K.","year":"2008","journal-title":"Pharmacol. Rep."},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2011.02.039"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2007.04.381"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2011.03590.x"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200317522"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17020189"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.3934\/publichealth.2016.2.407"},{"key":"e_1_2_7_40_1","unstructured":"Prince M. Wimo A. Guerchet M. Ali G. C.et\u00a0al. Alzheimer's Diseases International. The global impact of dementia. An analysis of prevalence incidence cost and trends.https:\/\/www.alz.co.uk\/research\/world\u2010report\u201020154th May2016."},{"key":"e_1_2_7_41_1","unstructured":"Duthey B. Bakground Paper 6.11. Alzheimer disease and other dementias.2013."},{"key":"e_1_2_7_42_1","unstructured":"Oliver N. Alzheimer's disease. Current status future perspectives.AMUS Meeting2013."},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-4580(95)00021-6"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a006189"},{"key":"e_1_2_7_45_1","unstructured":"FDA.U.S. Food and Drug Administration. U. S. Food and Drug Administration NAMENDA XR (memantine hydrochloride).http:\/\/www.fda.gov\/Drugs\/default.htm11th March2016."},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep04094"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.116.105130"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12600"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/hipo.22270"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.1996.tb01241.x"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.2174\/1567205053585846"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2005.09.007"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2014.05.011"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.071027"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2012.12.023"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3458.2003.tb00254.x"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-011-0561-0"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2010.05.004"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543776.2014.972938"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3728-09.2009"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11915"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn.3930"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2011.11.053"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2012.08.018"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2009-1071"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2009-1087"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2006.08.008"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2006.07.021"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-014-0563-8"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.foodchem.2012.04.148"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2011-110110"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2013.1601"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2011.08.036"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.4161\/chan.27471"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules21080974"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2010-01411"},{"key":"e_1_2_7_77_1","article-title":"Gas chromatography time\u2010of\u2010flight mass spectrometry (GC\u2010TOF\u2010MS)\u2010based metabolomics for comparison of caffeinated and decaffeinated coffee and its implications for Alzheimer's disease","volume":"9","author":"Chang K. L.","year":"2014","journal-title":"PLoS One"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2014.06.012"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2011.02.017"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/30.3.590"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2010-091387"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.1159\/000371710"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1331.2002.00421.x"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwf074"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejcn.1602495"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000266670.35219.0c"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2010-1404"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-150333"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-150374"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2010-101428"},{"key":"e_1_2_7_91_1","doi-asserted-by":"publisher","DOI":"10.1039\/C5FO00052A"},{"key":"e_1_2_7_92_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-2010-091249"},{"key":"e_1_2_7_93_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-160142"},{"key":"e_1_2_7_94_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25945"},{"key":"e_1_2_7_95_1","first-page":"407","volume-title":"The Maudsley prescribing guidelines","author":"Taylor D.","year":"2010"},{"key":"e_1_2_7_96_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1460-9568.1999.00627.x"},{"key":"e_1_2_7_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2003.12.006"},{"key":"e_1_2_7_98_1","unstructured":"Zigmond M. J. Burke R. Pathophysiology of Parkinson's disease. Neuropsychopharmacology: The Fifth Generation of Progress2002 1781\u20131793."},{"key":"e_1_2_7_99_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.bmb.a070990"},{"key":"e_1_2_7_100_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-211-45295-0_3"},{"key":"e_1_2_7_101_1","unstructured":"CKS.Parkinson's Disease. Clinical Topic.2016Apr 10http:\/\/www.cks.nhs.uk\/home"},{"key":"e_1_2_7_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60492-X"},{"key":"e_1_2_7_103_1","unstructured":"Scottish Intercollegiate Guidelines Network.Diagnosis and pharmacological management of Parkinson's disease: a national clinical guideline.2016Apr 10.http:\/\/www.sign.ac.uk"},{"key":"e_1_2_7_104_1","unstructured":"Tarsy D.Pharmacologic treatment of Parkinson disease.2016Apr 10 www.uptodate.com"},{"key":"e_1_2_7_105_1","unstructured":"INFAC.Enfermedad de Parkinson: Aspectos pr\u00e1cticos.2010."},{"key":"e_1_2_7_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-801022-8.00012-X"},{"key":"e_1_2_7_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2006.05.027"},{"key":"e_1_2_7_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2012.01.022"},{"key":"e_1_2_7_109_1","first-page":"1","article-title":"Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease","volume":"21","author":"Chen J. F.","year":"2001","journal-title":"J. Neurosci."},{"key":"e_1_2_7_110_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22630"},{"key":"e_1_2_7_111_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.1052"},{"key":"e_1_2_7_112_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.20.2674"},{"key":"e_1_2_7_113_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwr451"},{"key":"e_1_2_7_114_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwm338"},{"key":"e_1_2_7_115_1","doi-asserted-by":"publisher","DOI":"10.1111\/ggi.12123"},{"key":"e_1_2_7_116_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40734-016-0037-8"},{"key":"e_1_2_7_117_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a116960"},{"key":"e_1_2_7_118_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwh312"},{"key":"e_1_2_7_119_1","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0000000000000102"},{"key":"e_1_2_7_120_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867322666141215160015"},{"key":"e_1_2_7_121_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1994.tb03840.x"},{"key":"e_1_2_7_122_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200201000-00005"},{"key":"e_1_2_7_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2004.05.002"},{"key":"e_1_2_7_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(01)00813-9"},{"key":"e_1_2_7_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.04.020"},{"key":"e_1_2_7_126_1","doi-asserted-by":"publisher","DOI":"10.1111\/neup.12269"},{"key":"e_1_2_7_127_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000256715.13907.d3"},{"key":"e_1_2_7_128_1","first-page":"195","article-title":"Enfermedad con cuerpos de Lewy","volume":"24","author":"Otero J. L.","year":"2008","journal-title":"Rev. Med. Urug."},{"key":"e_1_2_7_129_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291713000494"},{"key":"e_1_2_7_130_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000187889.17253.b1"},{"key":"e_1_2_7_131_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a2cbd1"},{"key":"e_1_2_7_132_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.170"},{"key":"e_1_2_7_133_1","doi-asserted-by":"publisher","DOI":"10.3233\/JPD-150725"},{"key":"e_1_2_7_134_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24385"},{"key":"e_1_2_7_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60111-1"},{"key":"e_1_2_7_136_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26001"},{"key":"e_1_2_7_137_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2010.208264"},{"key":"e_1_2_7_138_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000174432.87383.87"},{"key":"e_1_2_7_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2005.06.003"},{"key":"e_1_2_7_140_1","first-page":"451","volume-title":"The Maudsley Prescribing Guidelines","author":"Taylor D.","year":"2010"},{"key":"e_1_2_7_141_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkh612"},{"key":"e_1_2_7_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2013.05.013"},{"key":"e_1_2_7_143_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharep.2014.07.006"},{"key":"e_1_2_7_144_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23866"},{"key":"e_1_2_7_145_1","unstructured":"WHO.Atlas. Multiple sclerosis resources in the world 2008.2008."},{"key":"e_1_2_7_146_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002818.pub2"},{"key":"e_1_2_7_147_1","unstructured":"NICE.Multiple sclerosis in adults: management.2016Jun 4 https:\/\/www.nice.org.uk\/guidance\/cg186"},{"key":"e_1_2_7_148_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4271-03.2004"},{"key":"e_1_2_7_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2014.06.029"},{"key":"e_1_2_7_150_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2015-312176"},{"key":"e_1_2_7_151_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512448108"},{"key":"e_1_2_7_152_1","doi-asserted-by":"publisher","DOI":"10.1159\/000096853"},{"key":"e_1_2_7_153_1","first-page":"189","article-title":"Dietary habits and multiple sclerosis. A retrospective study in Ferrara., Italy","volume":"16","author":"Tola M. R.","year":"1994","journal-title":"Acta Neurol."},{"key":"e_1_2_7_154_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2011.03596.x"},{"key":"e_1_2_7_155_1","first-page":"529","article-title":"Pentoxifylline: is it useful in multiple sclerosis?","volume":"32","author":"Prieto J. M.","year":"2001","journal-title":"Rev. Neurol."},{"key":"e_1_2_7_156_1","unstructured":"Drug Information.Rilutek (riluzole).2016Jun 4 www.centerwatch.com"},{"key":"e_1_2_7_157_1","first-page":"109","article-title":"Coffee increases antioxidant enzyme capacity in the brain of male G93A mice, an animal model of amyotrophic lateral sclerosis (ALS)","volume":"23","author":"Seevaratnam R.","year":"2009","journal-title":"FASEB J."},{"key":"e_1_2_7_158_1","doi-asserted-by":"publisher","DOI":"10.1002\/jnr.23185"},{"key":"e_1_2_7_159_1","doi-asserted-by":"publisher","DOI":"10.3109\/21678421.2015.1020813"},{"key":"e_1_2_7_160_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwr229"},{"key":"e_1_2_7_161_1","doi-asserted-by":"publisher","DOI":"10.1097\/EDE.0b013e3181632c5d"},{"key":"e_1_2_7_162_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0066-7"}],"container-title":["Molecular Nutrition &amp; Food Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmnfr.201600670","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mnfr.201600670","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T11:08:35Z","timestamp":1694603315000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mnfr.201600670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,22]]},"references-count":161,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1002\/mnfr.201600670"],"URL":"https:\/\/doi.org\/10.1002\/mnfr.201600670","archive":["Portico"],"relation":{},"ISSN":["1613-4125","1613-4133"],"issn-type":[{"value":"1613-4125","type":"print"},{"value":"1613-4133","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,22]]},"article-number":"1600670"}}